Humasis Co. Ltd (KQ:205470) — Market Cap & Net Worth
Market Cap & Net Worth: Humasis Co. Ltd (205470)
Humasis Co. Ltd (KQ:205470) has a market capitalization of $61.42 Million (₩90.64 Billion) as of May 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21077 globally and #1316 in its home market, demonstrating a 5.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humasis Co. Ltd's stock price ₩801.00 by its total outstanding shares 113153840 (113.15 Million). Analyse Humasis Co. Ltd (205470) cash conversion ratio to see how efficiently the company converts income to cash.
Humasis Co. Ltd Market Cap History: 2015 to 2026
Humasis Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $37.79 Million to $61.42 Million (4.19% CAGR).
Index Memberships
Humasis Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.02% | #628 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.02% | #628 of 1384 |
Weight: Humasis Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Humasis Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humasis Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Humasis Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $39.66 Million | $8.51 Billion | -$4.72 Billion | 0.00x | N/A |
| 2018 | $25.54 Million | $9.66 Billion | -$852.81 Million | 0.00x | N/A |
| 2019 | $26.01 Million | $9.15 Billion | -$1.23 Billion | 0.00x | N/A |
| 2020 | $177.74 Million | $45.72 Billion | $21.08 Billion | 0.00x | 0.01x |
| 2021 | $316.28 Million | $321.83 Billion | $151.20 Billion | 0.00x | 0.00x |
| 2022 | $273.18 Million | $471.27 Billion | $182.63 Billion | 0.00x | 0.00x |
| 2023 | $144.62 Million | $13.83 Billion | -$55.42 Billion | 0.01x | N/A |
| 2024 | $125.53 Million | $25.41 Billion | -$30.44 Billion | 0.00x | N/A |
Competitor Companies of 205470 by Market Capitalization
Companies near Humasis Co. Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Humasis Co. Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Humasis Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Humasis Co. Ltd's market cap moved from $37.79 Million to $ 61.42 Million, with a yearly change of 4.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩61.42 Million | -21.01% |
| 2025 | ₩77.76 Million | -38.06% |
| 2024 | ₩125.53 Million | -13.20% |
| 2023 | ₩144.62 Million | -47.06% |
| 2022 | ₩273.18 Million | -13.63% |
| 2021 | ₩316.28 Million | +77.95% |
| 2020 | ₩177.74 Million | +583.45% |
| 2019 | ₩26.01 Million | +1.83% |
| 2018 | ₩25.54 Million | -35.61% |
| 2017 | ₩39.66 Million | +5.47% |
| 2016 | ₩37.61 Million | -0.50% |
| 2015 | ₩37.79 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Humasis Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.42 Million USD |
| MoneyControl | $61.42 Million USD |
| MarketWatch | $61.42 Million USD |
| marketcap.company | $61.42 Million USD |
| Reuters | $61.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more